|
KMID : 1120220230140050418
|
|
Osong Public Health and Research Perspectives
2023 Volume.14 No. 5 p.418 ~ p.426
|
|
|
Evaluation of COVID-19 vaccine effectiveness in different high-risk facility types during a period of Delta variant dominance in the Republic of Korea: a cross-sectional study
|
|
Lee Min-Jei
Hwang Myung-Jae
Kim Dong-Seob
Park Seon-Kyeong
Choi Ji-Hyun
Lee Ji-Joo
Kim Jong-Mu
Kim Young-Man
Park Young-Joon
Gwack Jin
Lee Sang-Eun
|
|
|
Abstract
|
|
|
Objectives : We evaluated the effectiveness of coronavirus disease 2019 vaccination in high-risk facilities in the Republic of Korea during the period when the highly transmissible Delta variant was prevalent. Additionally, we aimed to explore any disparities in vaccine effectiveness (VE) across various types of institutions, specifically distinguishing between non-medical and medical establishments.
Methods : We examined 8 outbreak clusters covering 243 cases and 895 contacts from 8 high-risk facilities divided into 2 groups: group A (4 non-medical institutions) and group B (4 medical institutions). These clusters were observed from July 27, 2021 to October 16, 2021 for the attack rate (AR) and VE with respect to disease severity. A generalized linear model with a binomial distribution was used to determine the odds ratio (OR) for disease severity and death.
Results : AR was notably lower in group B (medical institutions). Furthermore, VE analysis revealed that group A exhibited higher effectivity for disease severity and death than group B. The OR for disease severity was 0.24 (95% confidence interval [CI], 0.03?2.16) for group A and 0.27 (95% CI, 0.12?0.64) for group B, with the OR for death at 0.12 (95% CI, 0.01?1.32) in group A and 0.34 (95% CI, 0.14?0.87) in group B.
Conclusion : Although VE may vary across institutions, our findings underscore the importance of implementing vaccinations in high-risk facilities. Customized vaccination programs, tailored response plans, and competent management personnel are essential for effectively addressing and mitigating public health challenges.
|
|
|
KEYWORD
|
|
|
Communicable diseases, COVID-19, COVID-19 vaccines, SARS-CoV-2, Vaccine efficacy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|